IP Library Granted Patent US 11,406,331
Granted Patent B2
US 11,406,331 · App. 15/916,258 · Granted Aug 9, 2022

Model based variable risk false glucose threshold alarm prevention mechanism

Inventor: Erwin Satrya Budiman (Fremont, CA)
Assignee: Abbott Diabetes Care Inc.
A61B5/746A61B5/002A61B5/0031A61B5/14503A61B5/14532A61B5/14546A61B5/6849A61B5/7275A61B5/7282G16H20/17G16H40/67
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,406,331
App. No.
15/916,258
Granted
Aug 9, 2022
Kind
B2
Abstract

Methods of determining when to activate an analyte, e.g. glucose, related alarm, such as a hypoglycemia alarm, of a continuous analyte monitor is provided. Also provided are systems, devices and kits.

Claims (56)

1. A method for monitoring an analyte concentration of a user, comprising:

receiving from an analyte sensor measurement data related to a user's analyte concentration, wherein at least a portion of the analyte sensor is transcutaneously positioned in contact with a bodily fluid of the user;

receiving meal intake information of the user by a user input on a display device;

determining the user's analyte concentration using the analyte sensor measurement data;

determining a best-estimate of the user's analyte concentration using the measurement data received from the analyte sensor and the meal intake information of the user;

determining whether the user's analyte concentration and the best-estimate are in agreement;

activating an alarm according to the determination whether the user's analyte concentration and the best-estimate are in agreement, wherein activating the alarm comprises adjusting one or more alarm parameters; and

causing a notification associated with the user's analyte concentration to be displayed on the display device in response to the activating of the alarm.

2. The method of claim 1 , wherein the meal intake information of the user comprises an amount of carbohydrates or an estimate of the amount of carbohydrates.

3. The method of claim 1 , wherein activating the alarm comprises providing a recommendation associated with the user's analyte concentration to the user.

4. The method of claim 3 , wherein providing the recommendation comprises displaying a recommended action for the user to take on a user interface.

5. The method of claim 4 , wherein the recommended action comprises a recommended exercise or diet.

6. The method of claim 3 , wherein the recommendation comprises a bolus of insulin to be delivered to the user.

7. The method of claim 6 , further comprising activating an insulin delivery device to deliver the bolus of insulin to the user.

8. The method of claim 1 , further comprising:

determining a speed or duration of absorption of a meal based on the meal intake information, wherein the best-estimate is determined at least in part based on the determined speed or duration of absorption.

9. The method of claim 8 , wherein the alarm is activated according to a timer selected based on a glucose concentration associated with the speed or duration of absorption of the meal.

10. The method of claim 9 , wherein the determining a glycemic index of a meal from the meal intake information; and

selecting a duration of the timer based at least in part on the glycemic index.

11. The method of claim 1 , wherein the meal intake information comprises a meal time.

12. The method of claim 1 , further comprising determining that when the user's analyte concentration and the best-estimate are in agreement, that an increased likelihood of a glycemic event exists.

13. The method of claim 1 , further comprising selecting the timer corresponding to the user's analyte concentration and the best-estimate.

14. The method of claim 1 , wherein the user's analyte concentration and the best-estimate are in agreement when the user's analyte concentration converges with the best-estimate.

15. The method of claim 1 , wherein the user's analyte concentration and the best-estimate are in agreement when the user's analyte concentration does not diverge from the best-estimate.

16. The method of claim 1 , wherein the user's analyte concentration and the best-estimate are in agreement when the user's analyte concentration and the best-estimate each indicates an abnormal glycemic condition for treatment or analysis.

17. The method of claim 1 , wherein the one or more alarm parameters comprises an alarm delay time.

18. The method of claim 1 , wherein the one or more alarm parameters comprises a threshold value related to the user's analyte concentration.

19. An analyte monitoring system, comprising:

an analyte sensor configured to be partially in contact with bodily fluid under a skin layer of a user to monitor a concentration of an analyte; and

a display device, configured to:

receive measurement data related to the user's concentration of the analyte from the analyte sensor;

receive meal intake information of the user by a user input on the display device;

determine the user's analyte concentration using the measurement data;

determine a best-estimate of the user's analyte concentration using the measurement data received from the analyte sensor and the meal intake information of the user;

determine whether the user's analyte concentration and the best-estimate are in agreement;

activate an alarm according to the determination whether the user's analyte concentration and the best-estimate are in agreement, wherein activating the alarm comprises adjusting one or more alarm parameters; and

cause a notification associated with the user's analyte concentration to be displayed in response to the activation of the alarm.

20. The system of claim 19 , wherein the meal intake information of the user comprises an amount of carbohydrates or an estimate of the amount of carbohydrates.

21. The system of claim 20 , wherein activating the alarm comprises providing a recommendation associated with the user's analyte concentration to the user.

22. The system of claim 21 , wherein providing the recommendation comprises at least displaying a recommended action for the user to take on a user interface of the display device.

23. The system of claim 22 , wherein the recommended action comprises a recommended exercise or diet.

24. The system of claim 19 , wherein the recommendation comprises a bolus of insulin to be delivered to the user.

25. The system of claim 19 , wherein the display device is further configured to:

determine a speed or duration of absorption of a meal based on the meal intake information, wherein the best-estimate is determined in part based on the speed or duration of absorption.

26. The system of claim 25 , wherein the alarm is activated according to a timer selected based on a glucose concentration associated with the speed or duration of absorption of the meal.

27. The system of claim 26 , wherein the determining a glycemic index of a meal from the meal intake information; and

selecting a duration of the timer based at least in part on the glycemic index.

28. The system of claim 19 , wherein the recommendation further comprises activating an insulin delivery device to deliver the bolus of insulin to the user.

29. The system of claim 19 , wherein the meal intake information comprises a meal time.

30. The system of claim 19 , wherein the display device is further configured to determine that when the user's analyte concentration and the best-estimate are in agreement, that an increased likelihood of a glycemic event exists.

31. The system of claim 19 , wherein the display device is further configured to select the timer corresponding to the user's analyte concentration and the best-estimate.

32. The system of claim 19 , wherein the user's analyte concentration and the best-estimate are in agreement when the user's analyte concentration converges with the best-estimate.

33. The system of claim 19 , wherein the user's analyte concentration and the best-estimate are in agreement when the user's analyte concentration does not diverge from the best-estimate.

34. The system of claim 19 , wherein the user's analyte concentration and the best-estimate are in agreement when the user's analyte concentration and the best-estimate each indicates an abnormal glycemic condition for treatment or analysis.

35. The system of claim 19 , wherein the one or more alarm parameters comprises an alarm delay time.

36. The system of claim 19 , wherein the one or more alarm parameters comprises a threshold value related to the user's analyte concentration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2018
From: BUDIMAN, ERWIN SATRYA
To: ABBOTT DIABETES CARE INC.
Reel/Frame 045186/0790 →
Continuity (4)
Continuation 15487365 · Apr 13, 2017
Continuation 14128583
Provisional Application 61553931 · Oct 31, 2011
Related Publication 20180192963A1 · Jul 12, 2018
Cited By (4)
US 1,068,516 US 1,083,640 US 1,083,977 US 1,137,686